Growth factors and their potential therapeutic applications for healing of musculoskeletal and other connective tissues

American Journal of Veterinary Research

Volumn 66, Issue 4, 2005, Pages 727-737

  Zachos, Terri A ^a   Bertone, Alicia L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 10; BONE MORPHOGENETIC PROTEIN 15; BONE MORPHOGENETIC PROTEIN 16; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 9; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH DIFFERENTIATION FACTOR 5; GROWTH FACTOR; INHIBIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OSTEOGENIC PROTEIN 1; OSTEOGENIN; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT BONE MORPHOGENETIC PROTEIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT DNA; RECOMBINANT GROWTH FACTOR; RECOMBINANT GROWTH HORMONE; RECOMBINANT PROTEIN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTERIOR CRUCIATE LIGAMENT RUPTURE; BONE DEVELOPMENT; BONE TRANSPLANTATION; CELL BASED GENE THERAPY; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DEVICE; DOSE RESPONSE; DRUG APPROVAL; DRUG HALF LIFE; DRUG MECHANISM; FRACTURE HEALING; FRACTURE NONUNION; GENE EXPRESSION; GENE THERAPY; HUMAN; MOLECULAR INTERACTION; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOARTHRITIS; PROTEIN PROTEIN INTERACTION; RECOMBINANT DNA TECHNOLOGY; REVIEW; SIGNAL TRANSDUCTION; SOFT TISSUE INJURY; SPECIES DIFFERENCE; TENDON DISEASE;

ANIMALS; CONNECTIVE TISSUE DISEASES; GROWTH SUBSTANCES; HUMANS; MUSCULOSKELETAL DISEASES; RECOMBINANT PROTEINS;

EID: 17544369645     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.727     Document Type: Review

References (125)

1. Day MJ, Butterworth SJ, Palmer MR, et al. Characterization of wear debris associated with aseptic loosening of a canine hip. J Comp Pathol 1998;119:89-93.
2. Edwards MR, Egger EL, Schwarz PD. Aseptic loosening of the femoral implant after cemented total hip arthroplasty in dogs: 11 cases in 10 dogs (1991-1995). J Am Vet Med Assoc 1997;211:580-586.
3. Dyce J, Olmstead ML. Removal of infected canine cemented total hip prostheses using a femoral window technique. Vet Surg 2002;31:552-560.
4. Halling KB, Lewis DD, Cross AR, et al. Complication rate and factors affecting outcome of olecranon osteotomies repaired with pin and tension-band fixation in dogs. Can Vet J 2002;43:528-534.
5. Cook JL, Tomlinson LF, Stoll MR, et al. Arthroscopic removal and curettage of osteochondrosis lesions on the lateral and medial trochlear ridges of the talus in two dogs. J Am Anim Hosp Assoc 2001;37:75-80.
6. Carter BG, Bertone AL, Weisbrode SE, et al. Influence of methylprednisolone acetate on osteochondral healing in exercised tarsocrural joints of horses. Am J Vet Res 1996;57:914-922.
7. Grondahl AM, Jansen JH, Teige J. Accessory ossification centers associated with osteochondral fragments in the extremities of horses. J Comp Pathol 1996;114:385-398.
8. Todhunter RJ, Freeman KP, Yeager FE, et al. Effects of exercise on the development of osteoarthritis in equine carpal joints with osteochondral defects. Vet Surg 1993;22:330-342.
9. Stromberg B, Rejno S. Osteochondrosis in the horse. I. A clinical and radiologic investigation of osteochondritis dissecans of the knee and hock joint. Acta Radiol Suppl 1978;378:139-152.
10. Anastasiou A, Skioldebrand E, Ekman S, et al. Ex vivo magnetic resonance imaging of the distal row of equine carpal bones: assessment of bone sclerosis and cartilage damage. Vet Radiol Ultrasound 2003;44:501-512.
11. Gordon WJ, Conzemius MG, Riedesel E, et al. The relationship between limb function and radiographic osteoarthrosis in dogs with stifle osteoarthrosis. Vet Surg 2003;32:451-454.
12. Mortellaro CM. Pathophysiology of osteoarthritis. Vet Res Commun 2003;27(suppl 1):75-78.
13. Fernihough JK, Innes JF, Billingham ME, et al. Changes in the local regulation of insulin-like growth factors I and II and insulin-like growth factor-binding proteins in osteoarthritis of the canine stifle joint secondary to cruciate ligament rupture. Vet Surg 2003; 32:313-323.
14. Edinger DT, Hayashi K, Hongyu Y, et al. Histomorphometric analysis of the proximal portion of the femur in dogs with osteoarthritis. Am J Vet Res 2000;61:1267-1272.
15. Kealy RD, Lawler DF, Ballam JM, et al. Evaluation of the effect of limited food consumption on radiographic evidence of osteoarthritis in dogs. J Am Vet Med Assoc 2000;217:1678-1680.
16. Kurocki K, Cook JL, Kreeger JM. Mechanisms of action and potential uses of hyaluronan in dogs with osteoarthritis. J Am Vet Med Assoc 2002;221:944-950.
17. Volk SW, Kapatkin AS, Haskins ME, et al. Gelatinase activity in synovial fluid and synovium obtained from healthy and osteoarthritic joints of dogs. Am J Vet Res 2003;64:1225-1233.
18. MacWilliams PS, Friedrichs KR. Laboratory evaluation and interpretation of synovial fluid. Vet Clin North Am Small Anim Pract 2003;33:153-178.
19. Breitschwerdt EB, Abrams-Ogg AC, Lappin MR, et al. Molecular evidence supporting Ehrlichia canis-like infection in cats. J Vet Intern Med 2002;16:642-649.
20. Ollier WE, Kennedy LJ, Thomson W et al. Dog MHC alleles containing the human RA shared epitope confer susceptibility to canine rheumatoid arthritis. Immunogenetics 2001;53:669-673.
21. Pfizer Animal Health. Proprietary market research, survey of 200 veterinarians. 1996. Available at: www.rimadyl.con/facts/index.html. Accessed Dec 1, 2003.
22. Hardie EM, Roe SC, Martin FR. Radiographic evidence of degenerative joint disease in geriatric cats: 100 cases (1994-1997). J Am Vet Med Assoc 2002;220:628-632.
23. Johnson JM, Johnson AL. Cranial cruciate ligament rupture. Pathogenesis, diagnosis, and postoperative rehabilitation. Vet Clin North Am Small Anim Pract 1993;23:717-733.
24. Miyasaka KC, Daniel DM, Stone ML. The incidence of knee ligament injuries in the general population. J Knee Surg 1991;4:3-8.
25. Teitz CC, Garrett WE Jr, Miniaci A, et al. Instructional Course Lectures, The American Academy of Orthopaedic Surgeons. Tendon problems in athletic individuals. J Bone Joint Surg Am 1997;46:569-582.
26. Silver IA, Brown PM, Goodship AE. A clinical and experimental study of tendon injury, healing and treatment in the horse. Equine Vet J Suppl 1983;1:1-43.
27. Dowling BA, Dart AJ, Hodgson DR, et al. The effect of recombinant equine growth hormone on the biomechanical properties of healing superficial digital flexor tendons in horses. Vet Surg 2002;31:320-324.
28. Sutter WW, Kaneps AJ, Bertone AL. Comparison of hematologic values and transforming growth factor-β and insulin-like growth factor concentrations in platelet concentrates obtained by use of buffy coat and apheresis methods from equine blood. Am J Vet Res 2004; 65:924-930.
29. Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell. 4th ed. New York: Garland Science, Taylor & Francis Group, 2002;492, 1294.
30. Wu D, Razzano P, Grande DA. Gene therapy and tissue engineering in repair of the musculoskeletal system. J Cell Biochem 2003;88:467-481.
31. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995;270:404-410.
32. Oligino TJ, Yao Q, Ghivizzani SC, et al. Vector systems for gene transfer to joints. Clin Orthop 2000;379(suppl):S17-S30.
33. Lieberman JR, Ghivizzani SC, Evans SC. Gene transfer approaches to the healing of bone and cartilage. Mol Ther 2002; 6:141-147.
34. Viggeswarapu M, Boden SD, Liu Y, et al. Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo. J Bone Joint Surg Am 2001;83:364-376.
35. Lieberman JR, Daluiski A, Einhorn TA. Current concepts review. The role of growth factors in the repair of bone: biology and clinical applications. J Bone Joint Surg Am 2002;84:1032-1044.
36. Linkart TA, Mohan S, Baylink DJ. Growth factors for bone growth and repair; IGF, TGF beta, and BMP. Bone 1996;19 (suppl 1):1S-12S.
37. Truumees E, Herkowitz HN. Alternatives to autologous bone harvest in spine surgery Univ Penn Orthop J 1999;12:77-88.
38. Lind M. Growth factors: possible new clinical tools. A review. Acta Orthop Scand 1996;67:407-417.
39. Linkart TA, Mohan S, Baylink DJ. Growth factors for bone growth and repair; IGE TGF β, and BM. Bone 1996;19(suppl 1):1-12.
40. Vortkamp A, Pathi S, Peretti GM, et al. Recapitulation of signals regulating embryonic bone formation during postnatal growth and in fracture repair. Mech Dev 1998;71:65-76.
41. Le AX, Miclau T, Hit D, et al. Molecular aspects of healing in stabilized and non-stabilized fractures. J Orthop Res 2001;19:78-84.
42. Ferguson CM, Alpern E, Miclau T, et al. Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev 1999;87:57-66.
43. Thompson Z, Miclau T, Hu D, et al. A model for intramembranous ossification during fracture healing. J Orthop Res 2002; 20:1091-1098.
44. Asano N, Yamakazi T, Seto M, et al. The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma. J Bone Joint Surg Br 2004;86:607-612.
45. Guo W, Gorlick R, Ladanyi M, et al. Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop 1999;365:175-183.
46. Robey PG, Young MF, Flanders KC, et al. Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro. J Cell Biol 1987;105:457-463.
47. Joyce ME, Jingushi S, Bolander ME. Transforming growth factor-beta in the regulation of fracture repair. Orthop Clin North Am 1990;21:199-209.
48. Lind M, Schumaker B, Soballe K, et al. Transforming growth factor beta enhances fracture healing in rabbit tibiae. Acta Orthop Scand 1993;64:553-556.
49. Nielsen HM, Andreassen TT, Ledet T, et al. Local injection of TGF-beta increases the strength of tibial fractures in the rat. Acta Orthop Scand 1994;65:37-41.
50. Critchlow MA, Bland TS, Ashurst DE. The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone 1995;16:521-527.
51. Ozkaynak E, Rueger DC, Drier EA, et al. OP-1 cDNA encodes an osteogenic protein in the TGF-beta family. EMBO J 1990; 9:2085-2093.
52. Wang EA, Rosen V, D'Alessandro JS, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A 1990;87:2220-2224.
53. Reddi AH. Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg Am 2001;83(suppl 1, part 1):S1-S6.
54. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-899.
55. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242:1528-1534.
56. Celeste AJ, Iannazzi JA, Taylor RC, et al. Identification of transforming growth factor β family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci U S A 1990;87:9843-9847.
57. Heckman JD, Boyan BD, Aufdemorte TB, et al. The use of bone morphogenetic protein in the treatment of nonunion in a canine model. J Bone Joint Surg Am 1991;73:750-764.
58. Sciadini MF, Dawson JM, Johnson KD. Evaluation of bovine-derived bone protein with a natural coral carrier as a bone-graft substitute in a canine segmental defect model. J Orthop Res 1997;15:844-857.
59. Sciadini MF, Johnson KD. Evaluation of recombinant human bone morphogenetic protein-2 as a bone graft substitute in a canine segmental defect model. J Orthop Res 2000;18:289-302.
60. Pluhar GE, Manley PA, Heiner JP et al. The effect of recombinant human bone morphogenetic protein-2 on femoral reconstruction with an intercalary allograft in a dog model. J Orthop Res 2001;19:308-317.
61. Zabka AG, Pluhar GE, Edwards RB III, et al. Histomorphometric description of allograft bone remodeling and union in a canine segmental femoral defect model: a comparison of rhBMP-2, cancellous bone graft, and absorbable collagen sponge. J Orthop Res 2001;19:318-327.
62. Muschler GF, Hyodo A, Manning T, et al. Evaluation of human bone morphogenetic protein 2 in a canine spinal fusion model. Clin Orthop 1994;308:229-240.
63. Sandhu HS, Kanim LEA, Kabo JM, et al. Evaluation of rhBMP-2 with an OPLA carrier in a canine posterolateral (transverse process) spinal fusion model. Spine 1995;20:2669-2682.
64. David SM, Gruber HE, Meyer RA Jr, et al. Lumbar spinal fusion using recombinant human bone morphogenetic protein in the canine. A comparison of three dosages and two carriers. Spine 1999;24:1973-1979.
65. Tatakis DN, Koh A, Jin L, et al. Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model: a dose-response study. J Periodontal Res 2002;37:93-100.
66. Sigurdsson TJ, Fu E, Tatakis DN, et al. Bone morphogenetic protein-2 for bone regeneration and osseointegration. Clin Oral Implants Res 1997;8:367-374.
67. Rodeo SA, Suzuki K, Deng XH, et al. Use of recombinant human bone morphogenetic protein-2 to enhance tendon healing in a bone tunnel. Am J Sports Med 1999;27:476-488.
68. Cook SD, Baffes GC, Wolfe MW, et al. Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. Clin Orthop 1994;301:302-312.
69. Cook SD, Barrack RL, Santman M, et al. Strut allograft healing to the femur with recombinant human osteogenic protein-1. Clin Orthop 2000;381:47-57.
70. Salkeld SL, Patron LP, Barrack RL, et al. The effect of osteogenic protein-1 on the healing of segmental bone defects treated with autograft or allograft bone. J Bone Joint Surg Am 2001;83:803-816.
71. Mont MA, Jones LC, Elias JJ, et al. Strut-autografting with and without osteogenic protein-1. J Bone Joint Surg Am 2001;83:1013-1022.
72. Cullinane DM, Lietman SA, Inoue N, et al. The effect of recombinant human osteogenic protein-1 (bone morphogenetic protein-7) impregnation on allografts in a canine intercalary bone defect. J Orthop Res 2002;20:1240-1245.
73. Trippel SB. Growth factors as therapeutic agents. Instr Course Lect 1997;46:473-476.
74. Andrew JG, Hoyland J, Freemont AJ, et al. Insulin-like growth factor gene expression in human fracture callus. Calcif Tissue Int 1993;53:97-102.
75. Bhaumick B, Bala RM. Differential effects of insulin-like growth factors I and II on growth, differentiation and glucoregulation in differentiating chondrocyte cells in culture. Acta Endocrinol (Copenh) 1991;125:201-211.
76. Canalis E, McCarthy TL, Centrella M. Effects of platelet-derived growth factor on bone formation in vitro. J Cell Physiol 1989;140:530-537.
77. Bak B, Jorgensen PH, Andreassen TT. Dose response of growth hormone on fracture healing in the rat. Acta Orthop Scand 1990;61:54-57.
78. Trippel S, Wroblewski J, Makower A, et al. Regulation of growth-plate chondrocytes by insulin-like growth factor I and basic fibroblast growth factor. J Bone Joint Surg Am 1993;75:177-189.
79. Frisbie DD, Nixon AJ. Insulin-like growth factor 1 and corticosteroid modulation of chondrocyte metabolic and mitogenic activities in interleukin 1-conditioned equine cartilage. (Erratum published in Am J Vet Res 1997;58:701.) Am J Vet Res 1997;58:524-530.
80. Frisbie DD, Sandler EA, Trotter GW, et al. Metabolic and mitogenic activities of insulin-like growth factor-1 in interleukin-1-conditioned equine cartilage. Am J Vet Res 2000;61:436-441.
81. Fortier LA, Lust G, Mohammed HO, et al. Coordinate upregulation of cartilage matrix synthesis in fibrin cultures supplemented with exogenous insulin-like growth factor-I. J Orthop Res 1999;17:467-474.
82. Worster AA, Brower-Toland BD, Fortier LA, et al. Chondrocytic differentiation of mesenchymal stem cells sequentially exposed to transforming growth factor-betal in monolayer and insulin-like growth factor-1 in a three-dimensional matrix. J Orthop Res 2001;19:738-749.
83. Fortier LA, Nixon AJ, Lust G. Phenotypic expression of equine articular chondrocytes grown in three-dimensional cultures supplemented with supraphysiologic concentrations of insulin-like growth factor-I. Am J Vet Res 2002;63:301-305.
84. Nixon AJ, Fortier LA, Williams J, et al. Enhanced repair of extensive articular cartilage defects by insulin-like growth factor-I-laden fibrin composites. J Orthop Res 1999;17:475-487.
85. Fortier LA, Balkman CE, Sandell LJ, et al. insulin-like growth factor-I gene expression patterns during spontaneous repair of acute articular cartilage injury. J Orthop Res 2001;19:720-728.
86. Fortier LA, Mohammed HO, Lust G, et al. Insulin-like growth factor-I enhances cell-based repair of articular cartilage. J Bone Joint Surg Br 2002;84:276-288.
87. Fernihough JK, Innes JF, Billingham MEJ, et al. Changes in local regulation of insulin-like growth factors I and II and insulin-like growth factor binding proteins in osteoarthritis of the canine stifle joint secondary to cruciate ligament rupture. Vet Surg 2003;32:313-323.
88. Martel-Pelletier J, DiBattista JA, Lajeunesse D, et al. IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis. Inflamm Res 1998;47:90-100.
89. Millis DL, Wilkens BE, Daniel GB, et al. Radiographic, densitometric, and biomechanical effects of recombinant canine somatotropin in an unstable ostectomy gap model of bone healing in dogs. Vet Surg 1998;27:85-93.
90. Vortkamp A, Lee K, Lanske B, et al. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 1996;273:613-622.
91. Cho T-J, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor-β superfamily during murine fracture healing. J Bone Miner Res 2002; 17:513-520.
92. Uusitalo H, Rantakokko J, Ahonen M, et al. A metaphyseal defect model of the femur for studies of murine bone healing. Bone 2001;28:423-429.
93. Iwasaki M, Le AX, Helms JA. Expression of Indian hedgehog, bone morphogenetic protein 6, and gli during skeletal morphogenesis. Mech Dev 1997;69:197-202.
94. Ferguson CM, Miclau T, Hu D, et al. Common molecular pathways in skeletal morphogenesis and repair. Ann N Y Acad Sci 1998;857:33-42.
95. Le AX, Miclau T, Hu D, et al. Molecular aspects of healing in stabilized and non-stabilized fractures. J Orthop Res 2001; 19:78-84.
96. Aldinger G, Herr G, Kusswetter W et al. Bone morphogenetic protein: a review. Int Orthop 1991;15:169-177.
97. Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 1992;32:160-167.
98. Boden SD. Clinical application of BMPs. Commentary. J Bone Joint Surg Am 2001;83(suppl 1, part 2):S161.
99. Govender S, Csimma C, Genant HK, et al. BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. J Bone Joint Surg Am 2002;84:2123-2134.
100. Maniscalco P, Gambera D, Bertone C, et al. Healing of fresh tibial fractures with OP-1. A preliminary report. Acta Biomed Ateneo Parmense 2002;73:27-33.
101. Friedlaender GE, Perry GR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001;83(suppl 1, part 2): S151-S158.
102. Boden SD, Kang J, Sandhu H, et al. Use of recombinant bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial. Spine 2002;27:2662-2673.
103. Burkus JK, Transfeldt EE, Kitchel SH, et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine 2002;27:2396-2408.
104. Burkus JK, Dorchak JD, Sanders DL. Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein type 2. Spine 2003;28:372-377.
105. Johnsson R, Stromqvist B, Aspenberg P. Randomized radiostereoisomeric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion. Spine 2002;27:2654-2661.
106. Martin GJ Jr, Boden SD, Marone MA, et al. Posterolateral intertransverse arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J Spinal Disord 1999;12:179-186.
107. Wozney JM. Bone morphogenetic proteins and their gene expression. In: Noda M, ed. Cellular and molecular biology of bone. New York: Academic Press Inc, 1993;131-167.
108. Winn SR, Uludag H, Hollinger JO. Carrier systems for bone morphogenetic proteins. Clin Orthop 1999;367S:S95-S106.
109. Li RH, Bouxsein CA, Blake CA, et al. rh BMP-2 injected in a calcium phosphate paste (alpha-BSM) accelerates healing in the rabbit ulnar osteotomy model. J Orthop Res 2003;21:997-1004.
110. Marx RE, Carlson ER, Eichstaedt RM, et al. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:638-646.
111. Furst G, Gruber R, Tangl S, et al. Sinus grafting with autogenous platelet-rich plasma and bovine hydroxyapatite. A histomorphometric study in minipigs. Clin Oral Implants Res 2003;14:500-508.
112. Kim SG, Kim WK, Park JC, et al. A comparative study of osseointegration of Avana implants in a demineralized freeze-dried bone alone or with platelet-rich plasma. J Oral Maxillofac Surg 2002;60:1018-1025.
113. Kim SG, Chung CH, Kim YK, et al. Use of particulate dentin-plaster of Paris combination with/without platelet-rich plasma in the treatment of bone defects around implants. Int J Oral Maxillofac Implants 2002;17:86-94.
114. Carter CA, Jolly DG, Worden CE, et al. Platelet-rich plasma gel promotes differentiation and regeneration during equine wound healing. Exp Mol Pathol 2003;74:244-255.
115. Yoo JU, Barthel TS, Nishimura K, et al. The chondrogenic potential of bone marrow-derived mesenchymal progenitor cells. J Bone Joint Surg Am 1998;80:1745-1757.
116. Finkemeier CG. Current concepts review: bone-grafting and bone-graft substitutes. J Bone Joint Surg Am 2002;84:454-464.
117. Devine MJ, Mierisch CM, Jang E, et al. Transplanted bone marrow cells localize to fracture callus in a mouse model. J Orthop Res 2002;20:1232-1239.
118. Tiedeman JJ, Connolly JF, Strates BS, et al. Treatment of nonunion by percutaneous injection of bone marrow and demineralized bone matrix. An experimental study in dogs. Clin Orthop 1991;268:294-302.
119. Connolly JF. Injectable bone marrow preparations to stimulate osteogenic repair. Clin Orthop 1995;313:8-18.
120. Connolly JF. Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis. Clin Orthop 1998;355(suppl):S257-S266.
121. Kadiyala S, Kraus KH, Attawia MA, et al. Rapid bone regeneration in femoral defects by an autologous osteoprogenitor cell concentrate using an intraoperative selective cell retention technique, in Proceedings. 49th Annu Meet Orthop Res Soc 2003;no. 317.
122. Brodke DS, Kapur TA, Pedrozo HA, et al. A bone graft prepared with selective cell retention technology heals canine segmental defects as effectively as autograft. Available at: www.cellectiveretention.com/cellect_files /obo9-60-000_canine_whitepaper.pdf. Accessed Jan 15, 2004.
123. Frisbie DD, Ghivizzani SC, Robbins PD, et al. Treatment of experimental equine osteoarthritis by in vivo delivery of equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9:12-20.
124. Bendele AM, Chlipala ES, Scherrer J, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000;43:2648-2659.
125. Gouze J-N, Gouze E, Palmer GD, et al. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer. Arthritis Res Ther 2003;5:R301-R309.